TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27575984

Group type: EXPERIMENTAL
Intervention: Zarit Burden Inventory (ZBI)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living (IADL)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory (NPI)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Change of MMSE, IADL, NPI, and etiologies
Number of subjects: 222
Study: 27576181

Group type: EXPERIMENTAL
Intervention: nCLE (needle-based confocal laser endomicroscopy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: nCLE
Number of subjects: 40
Study: 27576310

Group type: EXPERIMENTAL
Intervention: Bone loading exercise program plus calcium and vitamin D (CaD)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Risedronate plus calcium and vitamin D (CaD)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Calcium and vitamin D (CaD) alone (Control)
Number of subjects: 309
Study: 27576341

Group type: EXPERIMENTAL
Intervention: Flemish CARES
Number of subjects: 192
Study: 27576542

Group type: EXPERIMENTAL
Intervention: Qiagen PyroMark Q96 ID system (PSQ assay)
Number of subjects: 1128
Study: 27576559

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study: 27576691

Group type: EXPERIMENTAL
Intervention: Sintokamide A (SINT1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPI-002 (known AR AF-1 inhibitor)
Number of subjects: 0
Study: 27577191

Group type: EXPERIMENTAL
Intervention: Patient Assisted Intervention for Neuropathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27579170

Group type: EXPERIMENTAL
Intervention: Self-report athlete monitoring system
Number of subjects: 100
Study: 27580059

Group type: EXPERIMENTAL
Intervention: Respiratory virus infections
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Human rhinoviruses
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Continued rhinovirus detections
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Respiratory viruses
Number of subjects: 157
Study: 27580835

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Non-reperfused patients
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Academic PCI centres
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Non-academic PCI centres
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Manual thrombectomy
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent implantation
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: TIMI risk score ≥4
Number of subjects: 1024
Study: 27581055

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-fat diet
Number of subjects: 715

Group type: COMPARATOR
Intervention: High-carbohydrate/low-fat diet
Number of subjects: 715
Study: 27581207

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg/day
Number of subjects: 41
Study: 27581438

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13), single dose
Number of subjects: 17
Study: 27581469

Group type: EXPERIMENTAL
Intervention: Pregnancy with depleted iron stores (SF <12 μg/L)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Overall cohort of women studied
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Erythropoietin levels during pregnancy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Inflammation at delivery
Number of subjects: 83
Study: 27581477

Group type: EXPERIMENTAL
Intervention: Maternal protein intake during pregnancy (mean second-trimester protein intake: 1.4 g · kg)
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Maternal protein intake during pregnancy
Number of subjects: 1961
Study: 27581518

Group type: EXPERIMENTAL
Intervention: Recombinant human EPO (rhEPO) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutralizing antibodies against EPOR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of EPOR by short interfering RNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Co-cultures of primary myeloma cells with bone marrow-derived stroma cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: High levels of EPOR mRNA
Number of subjects: 0
Study: 27581680

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/day) for 180 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/day)
Number of subjects: 0
Study: 27581751

Group type: EXPERIMENTAL
Intervention: CRM with sigmoidal prior skeleton
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CRM with conservative prior skeleton
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CRM with other prior skeleton approaches
Number of subjects: 6

Group type: COMPARATOR
Intervention: 3 + 3 method
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CRM approaches (all)
Number of subjects: 6
Study: 27582171

Group type: EXPERIMENTAL
Intervention: IGSC 20%
Number of subjects: 74
Study: 27582220

Group type: EXPERIMENTAL
Intervention: Aducanumab (human monoclonal antibody) administered via monthly intravenous infusions for one year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aducanumab
Number of subjects: 0
Study: 27582480

Group type: EXPERIMENTAL
Intervention: Treatment program for WTC dust exposure
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Improvement in lung function measured with forced oscillometry techniques
Number of subjects: 798
Study: 27582784

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 593
Study: 27583200

Group type: EXPERIMENTAL
Intervention: Short, frequent breaks from sitting (1-2 min every half hour; SB)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Longer, planned breaks from sitting (two 15-minute breaks per workday; LB)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Short, frequent breaks from sitting (SB)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Longer, planned breaks from sitting (LB)
Number of subjects: 49
Study: 27583202

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling (LIFE)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 113
Study: 27583276

Group type: EXPERIMENTAL
Intervention: CoQ10 (2,400 mg/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 27583313

Group type: EXPERIMENTAL
Intervention: rIX-FP
Number of subjects: 27
Study: 27583590

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg once-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher unboosted doses or splitting the daily dose to twice-daily
Number of subjects: 0
Study: 27583892

Group type: EXPERIMENTAL
Intervention: NOACs (non-vitamin K antagonist oral anticoagulants) - appropriate treatment (AT)
Number of subjects: 2086

Group type: EXPERIMENTAL
Intervention: NOACs (non-vitamin K antagonist oral anticoagulants) - undertreatment (UT)
Number of subjects: 2086

Group type: EXPERIMENTAL
Intervention: NOACs (non-vitamin K antagonist oral anticoagulants) - overtreatment (OT)
Number of subjects: 2086

Group type: EXPERIMENTAL
Intervention: Independent predictors of undertreatment (UT)
Number of subjects: 2086

Group type: EXPERIMENTAL
Intervention: Independent predictors of overtreatment (OT)
Number of subjects: 2086
Study: 27584017

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 44
Study: 27585544

Group type: EXPERIMENTAL
Intervention: hrHPV infection (any of the 14 hrHPV types)
Number of subjects: 30829

Group type: EXPERIMENTAL
Intervention: HPV16 and/or HPV18 (HPV16/18)
Number of subjects: 30829

Group type: EXPERIMENTAL
Intervention: Age-specific prevalence of hrHPV
Number of subjects: 30829

Group type: EXPERIMENTAL
Intervention: Age-specific prevalence of HPV16/18
Number of subjects: 30829

Group type: EXPERIMENTAL
Intervention: Risk factors for hrHPV infections
Number of subjects: 30829
Study: 27585663

Group type: EXPERIMENTAL
Intervention: Oxytocin levels in craniopharyngioma patients with surgical hypothalamic lesions grade 1 (anterior hypothalamic area)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oxytocin levels in craniopharyngioma patients
Number of subjects: 34
Study: 27586250

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 76
Study: 27586634

Group type: EXPERIMENTAL
Intervention: High-resolution MRI, power Doppler ultrasound, and near-infrared imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions that increase lymphatic egress from diseased joints
Number of subjects: 0
Study: 27586869

Group type: EXPERIMENTAL
Intervention: Frequent exacerbations (FE) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrequent exacerbations (IE) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 27586891

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg daily for 4 weeks
Number of subjects: 30
Study: 27587380

Group type: EXPERIMENTAL
Intervention: First salvage treatment
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Second salvage treatment
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Third or greater salvage treatment
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Patients diagnosed from 2005 onward
Number of subjects: 1706
Study: 27587547

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27587708

Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Open-field imaging device
Number of subjects: 15
Study: 27588424

Group type: EXPERIMENTAL
Intervention: Drisapersen, 6 mg/kg subcutaneously, once weekly for 72 weeks, followed by intermittent dosing for 108 weeks (total 188 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Drisapersen
Number of subjects: 12
Study: 27589870

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-operative morbidity (measured using Post-Operative Morbidity Survey (POMS))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient related quality of life (measured using EQ-5D-5 L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-year mortality following surgery
Number of subjects: 0
Study: 27590145

Group type: COMPARATOR
Intervention: CC-930 (JNK inhibitor)
Number of subjects: 28
Study: 27590179

Group type: EXPERIMENTAL
Intervention: Quality assurance protocols in data collection for the intervention study
Number of subjects: 0
Study: 27590443

Group type: EXPERIMENTAL
Intervention: PLUS-M T-scores
Number of subjects: 199
Study: 27590592

Group type: EXPERIMENTAL
Intervention: ESCID
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ESCID facial expression
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ESCID calmness
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ESCID muscle tone
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ESCID compliance with mechanical ventilation
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ESCID consolability
Number of subjects: 286
Study: 27590665

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 38
Study: 27590962

Group type: EXPERIMENTAL
Intervention: Cecal insertion time quartiles
Number of subjects: 1043
Study: 27591241

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 127
Study: 27591348

Group type: EXPERIMENTAL
Intervention: Animated, 15-minute whiteboard video
Number of subjects: 101
Study: 27592805

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 88
Study: 27593452

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal weight children
Number of subjects: 92
Study: 27594805

Group type: EXPERIMENTAL
Intervention: Ambulance nurses (ANs) who attended the cardiovascular nursing (CVN) course (n=332)
Number of subjects: 1747

Group type: COMPARATOR
Intervention: Ambulance nurses (ANs) who did not attend the cardiovascular nursing (CVN) course (n=1415)
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: Ambulance nurses (ANs) who attended the cardiovascular nursing (CVN) course
Number of subjects: 1747

Group type: COMPARATOR
Intervention: Ambulance nurses (ANs) who did not attend the cardiovascular nursing (CVN) course
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: Survival to 30 days
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: Final diagnosis
Number of subjects: 1747
Study: 27595276

Group type: EXPERIMENTAL
Intervention: TAPS tool (interviewer-administered)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: TAPS tool (self-administered)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: TAPS tool
Number of subjects: 2000
Study: 27595685

Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based guidelines through a national quality enhancement registry.
Number of subjects: 35616

Group type: EXPERIMENTAL
Intervention: Monthly benchmarked hospital quality reports and recognition of hospital quality achievement.
Number of subjects: 35616
Study: 27595689

Group type: EXPERIMENTAL
Intervention: Bone marrow cell (BMC) transplantation
Number of subjects: 0
Study: 27596535

Group type: EXPERIMENTAL
Intervention: Echocardiography and NT-proBNP levels
Number of subjects: 111
Study: 27597399

Group type: EXPERIMENTAL
Intervention: Tailored education about child passenger safety via the SIS smartphone app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tailored education about fire safety via the SIS smartphone app
Number of subjects: 0
Study: 27597733

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg intravenous bolus, dosing determined by up-and-down method)
Number of subjects: 50
Study: 27597740

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept administered at baseline and at 1, 2, and 4 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 29
Study: 27597811

Group type: EXPERIMENTAL
Intervention: Bioimpedance analysis (BIA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline VL measurements
Number of subjects: 60
Study: 27597895

Group type: EXPERIMENTAL
Intervention: Transepithelial corneal cross-linking using iontophoresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dresden protocol for corneal cross-linking
Number of subjects: 0
Study: 27597981

Group type: EXPERIMENTAL
Intervention: Delta-PCT
Number of subjects: 114

Group type: COMPARATOR
Intervention: Absolute PCT
Number of subjects: 114

Group type: COMPARATOR
Intervention: Percentage change in PCT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Optimal cut-off value for delta-PCT
Number of subjects: 114
Study: 27599006

Group type: EXPERIMENTAL
Intervention: Hormonal Contraception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 27599452

Group type: EXPERIMENTAL
Intervention: Tablet-based training to engage with Personal Health Record (PHR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic access to PHR without additional training
Number of subjects: 0
Study: 27599546

Group type: EXPERIMENTAL
Intervention: Spontaneous (transgenic) MM
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Transplanted MM
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High disease burden
Number of subjects: 2
Study: 27599602

Group type: EXPERIMENTAL
Intervention: Uterine balloon tamponade using a condom catheter
Number of subjects: 151
Study: 27599727

Group type: EXPERIMENTAL
Intervention: Flow measured at valve level (SVV)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Flow measured at the sinotubular junction (SVST)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Volumetric measurement (SVref)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Mean difference between SVref and SVV
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Mean difference between SVref and SVST
Number of subjects: 121
Study: 27599985

Group type: EXPERIMENTAL
Intervention: OSA50
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: P-SAP
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: STOP-Bang
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: DES-OSA
Number of subjects: 1584
Study: 27600044

Group type: EXPERIMENTAL
Intervention: Voriconazole administration
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no voriconazole)
Number of subjects: 61
Study: 27600314

Group type: EXPERIMENTAL
Intervention: Relational Work Scale (RWS) used to rate therapist interventions focusing on patients' relationships.
Number of subjects: 20
Study: 27600385

Group type: EXPERIMENTAL
Intervention: Insulin Detemir (IDet) + Insulin Aspart (IAsp)
Number of subjects: 177
Study: 27600462

Group type: EXPERIMENTAL
Intervention: High NLR group (NLR tertile 3)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Low NLR group (NLR tertile 1)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intermediate NLR group (NLR tertile 2)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 123
Study: 27601429

Group type: EXPERIMENTAL
Intervention: Self-expanding CoreValve bioprosthesis
Number of subjects: 0
Study: 27601462

Group type: EXPERIMENTAL
Intervention: First kinase inhibitor (KI) therapy (ibrutinib or idelalisib)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Subsequent salvage therapy following KI discontinuation
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Alternate KI in KI-intolerant patients
Number of subjects: 178

Group type: COMPARATOR
Intervention: Initial KI choice
Number of subjects: 178

Group type: COMPARATOR
Intervention: Richter transformation (RT)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) from KI initiation
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS) from KI initiation
Number of subjects: 178
Study: 27601554

Group type: EXPERIMENTAL
Intervention: AZD1775 as monotherapy (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD1775 in combination with gemcitabine (1,000 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD1775 in combination with cisplatin or carboplatin
Number of subjects: 0
Study: 27602207

Group type: EXPERIMENTAL
Intervention: Mothers screening for malnutrition by MUAC
Number of subjects: 12929

Group type: COMPARATOR
Intervention: Community health workers screening for malnutrition by MUAC
Number of subjects: 12929
Study: 27602228

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pool Exercise (PE)
Number of subjects: 34
Study: 27602311

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (20 million cells implanted once into the nonunion site using a fluoroscopic guide) in combination with platelet lysate (PL) product
Number of subjects: 7
Study: 27602761

Group type: EXPERIMENTAL
Intervention: ctDNA profiling
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ctDNA assay results
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ctDNA criteria
Number of subjects: 18
Study: 27602967

Group type: EXPERIMENTAL
Intervention: 20 mg/ml hyaluronic acid filler (Juvéderm Voluma® XC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Future recommendations for outcome measures
Number of subjects: 20
Study: 27603290

Group type: EXPERIMENTAL
Intervention: Streamlined delivery of antiretroviral therapy (ART) regardless of CD4 cell count, following community-wide HIV-testing.
Number of subjects: 5683

Group type: EXPERIMENTAL
Intervention: Streamlined delivery of ART for patients newly linking to care.
Number of subjects: 5683

Group type: EXPERIMENTAL
Intervention: Streamlined delivery of ART for patients previously in care.
Number of subjects: 5683

Group type: EXPERIMENTAL
Intervention: Streamlined delivery of ART with valid viral load results.
Number of subjects: 5683
Study: 27604186

Group type: COMPARATOR
Intervention: High dose sunitinib (20 μM for 6-9 h in vitro; once-weekly in vivo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard daily sunitinib (50 mg daily, four weeks on, two weeks off)
Number of subjects: 0
Study: 27604397

Group type: EXPERIMENTAL
Intervention: Pepsin in saliva from patients undergoing 24-hour MII/pH monitoring
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pepsin in saliva from asymptomatic controls
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pepsin concentration in saliva samples collected within 2 hours after reflux event
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pepsin concentration in saliva samples collected more than 2 hours after reflux event
Number of subjects: 90
Study: 27604543

Group type: EXPERIMENTAL
Intervention: Computer-assisted social network motivational interviewing intervention
Number of subjects: 11
Study: 27604771

Group type: EXPERIMENTAL
Intervention: Lean pork ingestion
Number of subjects: 10
Study: 27604773

Group type: EXPERIMENTAL
Intervention: White bread (GI value determined by standardized methodology)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Insulin index and glycated hemoglobin values
Number of subjects: 63
Study: 27604981

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide treatment
Number of subjects: 50
Study: 27605156

Group type: EXPERIMENTAL
Intervention: Bortezomib and thalidomide therapy
Number of subjects: 172
Study: 27605368

Group type: COMPARATOR
Intervention: ICG-qualitative TSH test kit
Number of subjects: 283

Group type: COMPARATOR
Intervention: ICG-quantitative TSH analysis system
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Third-generation serum TSH assay
Number of subjects: 283
Study: 27605539

Group type: EXPERIMENTAL
Intervention: DCV+SOF
Number of subjects: 485

Group type: COMPARATOR
Intervention: DCV+SOF+RBV
Number of subjects: 485
Study: 27606973

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) treatment
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy
Number of subjects: 303
Study: 27607476

Group type: COMPARATOR
Intervention: Short-acting opioids (fentanyl)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Long-acting opioids (morphine and/or hydromorphone)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Comparison of long-acting vs short-acting opioids
Number of subjects: 191